This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Symbicort SMART (Symbicort Maintenance And Reliever Therapy) (SMART)

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: August 29, 2007
Last updated: July 10, 2009
Last verified: July 2009
The purpose of this study is to investigate the extent of Symbicort use in patients prescribed Symbicort as maintenance and reliever therapy.


Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: SMART (Symbicort Maintenance And Reliever Therapy): Reassure Program for Patients Using Symbicort Turbuhaler as Maintenance and Reliever Therapy in Korean Clinical Practice

Further study details as provided by AstraZeneca:

Estimated Enrollment: 2000
Study Start Date: July 2007
Study Completion Date: July 2008

Ages Eligible for Study:   12 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Hospital Outpatient Clinics

Inclusion Criteria:

  • Asthma patients prescribed Symbicort as maintenance and reliever therapy, according to the label, before inclusion in this program.

Exclusion Criteria:

  • Since this programme intends to describe Symbicort use in routine clinical practice when prescribed as Symbicort maintenance and reliever therapy, there are no programme specific exclusion criteria, other than: involvement in the planning and conduct of the programme (applies to both AstraZeneca staff or staff at the investigational site)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00523679

Korea, Republic of
Research Site
Seoul, Jongro-gu, Korea, Republic of
Research Site
Seoul, Kangnam-gu, Korea, Republic of
Research Site
Seoul, Songpa-gu, Korea, Republic of
Sponsors and Collaborators
Study Director: Joon-Woo Bahn AstraZeneca Korea
  More Information

Additional Information: Identifier: NCT00523679     History of Changes
Other Study ID Numbers: NIS-RKR-SYM-2007/1
Study First Received: August 29, 2007
Last Updated: July 10, 2009

Keywords provided by AstraZeneca:

Additional relevant MeSH terms:
Budesonide, Formoterol Fumarate Drug Combination
Anti-Asthmatic Agents
Respiratory System Agents processed this record on September 21, 2017